Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis
| العنوان: | Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis |
|---|---|
| المؤلفون: | Shuang Li, Ying Cheng, Shuang Zhang |
| المصدر: | Thoracic Cancer |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Male, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, immune checkpoint inhibitor, 03 medical and health sciences, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Internal medicine, medicine, Biomarkers, Tumor, Humans, Adverse effect, Neoplasm Staging, Chemotherapy, business.industry, Incidence (epidemiology), Hazard ratio, General Medicine, Immunotherapy, Original Articles, Small Cell Lung Carcinoma, Progression-Free Survival, Clinical trial, 030104 developmental biology, First‐line treatment, meta‐analysis, 030220 oncology & carcinogenesis, Meta-analysis, Female, Original Article, small cell lung cancer, business, PD-L1 inhibitor |
| الوصف: | Background Immunotherapy has afforded new treatment options for extensive small cell lung cancer (ES‐SCLC). However, reports on the effectiveness of immune checkpoint inhibitors (ICIs) combined with chemotherapy on survival in ES‐SCLC patients are inconsistent. Therefore, we conducted a meta‐analysis on the efficacy and safety of ICI combined with chemotherapy for ES‐SCLC. Methods We searched for randomized controlled clinical trials related to first‐line treatment of ES‐SCLC with ICI combined with chemotherapy in PUBMED, ESMO, ASCO, and WCLC since 2018. The primary outcome was overall survival (OS). Results Four studies were included. Compared to chemotherapy alone, ICI in combination with chemotherapy as first‐line treatment reduced the risk of death (hazard ratio [HR]: 0.76; 95% CI: 0.68–0.86; P This is a meta‐analysis evaluated the efficacy and safety of PD‐L1/PD‐1 immunotherapy combined with first‐line chemotherapy for extensive small cell lung cancer. A total of 1538 patients from four trials were included in our meta‐analysis. Our study proved that PD‐L1/PD‐1 immunotherapy combined with chemotherapy can significantly improve the OS and PFS of first‐line ES‐ SCLC. |
| تدمد: | 1759-7714 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a87475d0ea5c1621ac79cc4a9f6e09d4Test https://pubmed.ncbi.nlm.nih.gov/33058504Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a87475d0ea5c1621ac79cc4a9f6e09d4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 |
|---|